新诊断房颤患者早期死亡、卒中/系统性栓塞及大出血风险
基于GARFIELD-AF登记中52 014例新诊断房颤患者,评估12个月内早期事件风险。1个月内死亡率为6.8/100人年,卒中/系统性栓塞为2.3/100人年,大出血为1.5/100人年;早期死亡主要归因于心血管死亡,尤其是心衰、猝死和急性冠脉综合征。
要点
- 新诊断房颤后1个月内死亡、卒中/栓塞及大出血风险均较高。
- 1个月死亡主要归因于心血管死亡,其中心衰、猝死和急性冠脉综合征多见。
- 抗凝治疗与欧洲或亚洲居住是早期死亡风险较低的独立预测因素。
核心结论
- 新诊断房颤患者早期事件风险增加,尤其心血管死亡,提示需全面管理并警惕早期死亡预警信号。
研究设计与样本
- 前瞻性队列研究,纳入GARFIELD-AF登记中2010年3月至2016年8月期间52 014例新诊断房颤患者,评估12个月内早期事件风险。
主要发现
- 12个月内2140例死亡(死亡率4.3/100人年,95%CI 4.2-4.5),其中288例(13.5%)死于第一个月(6.8/100人年,95%CI 6.1-7.6)。
- 12个月内657例发生卒中/系统性栓塞(1.3/100人年,95%CI 1.2-1.4),411例发生大出血(0.8/100人年,95%CI 0.8-0.9)。
- 第一个月卒中/系统性栓塞率为2.3/100人年(95%CI 1.9-2.8),大出血率为1.5/100人年(95%CI 1.2-1.9)。
- 1个月死亡率升高主要归因于心血管死亡(3.5/100人年,95%CI 3.0-4.1),中心衰、猝死和急性冠脉综合征分别为1.0(95%CI 0.8-1.4)、0.6(95%CI 0.4-0.8)和0.5(95%CI 0.3-0.8)/100人年。
- 年龄、心衰、既往卒中、肝硬化史、血管疾病、中重度肾病、糖尿病及居住于北美或拉丁美洲是早期死亡风险较高的独立预测因素;抗凝治疗及居住于欧洲或亚洲是早期死亡风险较低的独立预测因素。
关键数值与推荐
- 1个月死亡风险预测模型的C统计量为0.81(95%CI 0.78-0.83)。
临床怎么用
- 对新诊断房颤患者应全面评估并密切监测早期死亡、卒中/栓塞及出血风险,尤其关注心衰、猝死和急性冠脉综合征等心血管事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolism, and bleeding (incurred by antithrombotic therapy), which may occur early after diagnosis. METHODS: We assessed the risk of early events (death, stroke/systemic embolism, and major bleeding) over 12 months and their relation to the time after diagnosis of atrial fibrillation in 52 014 patients prospectively enrolled in the GARFIELD-AF registry (Global Anticoagulant Registry in the FIELD-Atrial Fibrillation) between March 2010 and August 2016. RESULTS: Over 12 months, 2140 patients died (mortality rate, 4.3; 95% CI, 4.2-4.5 per 100 person-years), of whom 288 (13.5%) died in the first month (6.8; 95% CI, 6.1-7.6). Over 12 months, 657 patients had a stroke/systemic embolism (1.3; 95% CI, 1.2-1.4) and 411 had a major bleeding (0.8; 95% CI, 0.8-0.9). During the first month, the rates (per 100 person-years) of stroke/systemic embolism and major bleed were 2.3 (95% CI, 1.9-2.8) and 1.5 (95% CI, 1.2-1.9), respectively. The elevated 1-month mortality rate was mostly attributable to cardiovascular mortality (3.5; 95% CI, 3.0-4.1), in particular, heart failure, sudden death, and acute coronary syndromes (1.0 [95% CI, 0.8-1.4], 0.6 [95% CI, 0.4-0.8], and 0.5 [95% CI, 0.3-0.8], respectively). Age, heart failure, prior stroke, history of cirrhosis, vascular disease, moderate-to-severe kidney disease, diabetes mellitus, and living in North or Latin America were independent predictors of a higher risk of early death, whereas anticoagulation and living in Europe or Asia were independent predictors of a lower risk of early death. A predictive model developed for the 1-month risk of death had a C-statistic of 0.81 (95% CI, 0.78-0.83). CONCLUSIONS: The increased hazard of early events, in particular, cardiovascular mortality, in newly diagnosed atrial fibrillation points to the importance of comprehensive care for such patients and should alert clinicians to detect warning signs of possible early mortality. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01090362.
引用
- Bassand JP, Virdone S, Goldhaber SZ, et al. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation. 2019. PMID: 30586740. doi:10.1161/CIRCULATIONAHA.118.035012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。